Figure 1.

LCMV Cl13 persists in small intestinal mesenchymal and hematopoietic, but not epithelial, cells and increases intestinal permeability to small molecules. See also Fig. S1 and Fig. S2.C57BL/6 mice were infected with LCMV ARM or Cl13 or left uninfected and analyzed at indicated time points p.i. (A, C, and D) Representative immunofluorescence staining of ileum sections with anti-LCMV Abs (red) and DAPI (blue), as well as anti-Vimentin (green) or anti-CD45.2 (cyan) Abs (C) or anti-EpCAM (green) Ab (D). Arrowheads highlight regions of overlap between markers. Scale bars represent 230 µm (A) or 36 µm (C and D). (B) LCMV PFUs in ileum and colon; limit of detection (LOD) is indicated by dotted lines. (E) Mander’s overlap coefficient between LCMV and EpCAM, Vimentin, or CD45 markers. (F) In vivo intestinal permeability to FD4 was measured in ARM- and Cl13-infected mice and normalized to levels in uninfected mice. Averages (E) and averages ± SEM (B and F) are shown. Data are representative of two independent experimental repeats (A–E) or pooled from two independent experimental repeats (F) with n = 3–8 mice/group. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001; Kolmogorov–Smirnov test (F). n.s., not significant.